摘要
癌症是全球第二大死亡原因,而肺癌是发病率和病死率增长最快、对人们健康和生命威胁最大的恶性肿瘤之一。近年来,中药活性成分防治肿瘤的研究越来越深入。黄芪是常用的抗肿瘤中药之一,入药已有2000多年历史,被誉为“补气补脾诸药之最”。黄芪甲苷(AstragalosideⅣ,AS-Ⅳ)是黄芪主要活性成分之一,现代药理研究表明AS-Ⅳ具有抗癌、抗炎、抗氧化和免疫调节等作用。通过收集近年来国内外AS-Ⅳ抗肿瘤机制,梳理其抑制肿瘤细胞增殖、诱导肿瘤细胞凋亡、抑制肿瘤细胞迁移与侵袭、抑制上皮细胞-间充质转化(Epithelial-mesenchymal transition,EMT)、调节自噬、调节免疫反应应答、减轻肿瘤治疗过程中不良反应、增强抗肿瘤药物敏感性等作用,综述其在肺癌中的研究进展,以期支持AS-Ⅳ进一步研究、开发及应用,为其投入临床使用提供参考依据。
Cancer is the second leading cause of death worldwide,and lung cancer is one of the malignant tumours with the fastest growing morbidity and mortalit and the greatest threat to people's health and lives.In recent years,the research on active ingredients of traditional Chinese medicine to prevent and treat tumours has become more and more in-depth.Huangqi(Astragali Radix)is one of the commonly used anti-tumour Chinese medicines,which has been used in medicine for more than 2000 years,and has been regarded as“the most important medicine for replenishing Qi and spleen”.AstragalosideⅣ(AS-Ⅳ)is one of the main active ingredients of Huangqi(Astragali Radix),and modern pharmacological studies have shown that AS-Ⅳhas anticancer,anti-inflammatory,antioxidant and immunomodulatory effects.This paper reviewed the research progress of AS-Ⅳin lung cancer by collecting and summarizing the mechanisms of AS-Ⅳin inhibiting tumor cell proliferation,inducing tumor cell apoptosis,inhibiting tumor cell migration and invasion,suppressing epithelial-mesenchymal transition(EMT),regulating autophagy,modulating immune response,alleviating toxic side effects during tumor treatment and enhancing sensitivity to anti-tumor drugs.The aim was to provide a reference for further research,development and application of AS-Ⅳin order to support its clinical use.
作者
杨振耀
张晓青
王成志
张山
赵戈蕾
刘培民
李东东
YANG Zhenyao;ZHANG Xiaoqing;WANG Chengzhi;ZAHNG Shan;ZHAO Gelei;LIU Peimin;LI Dongdong(The Second Afiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450002,Henan,China;The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,China)
出处
《中华中医药学刊》
北大核心
2025年第4期187-192,I0037,共7页
Chinese Archives of Traditional Chinese Medicine
基金
国家自然科学基金项目(82204981)
国家中医临床研究基地科研专项(2021JDZX2002)
河南省特色骨干学科中医学学科建设项目(STG-ZYX06-202145)
河南省中医药科学研究专项(20-21ZY2115)
河南省中医院博士科研基金项目(2022BSJJ08,2023BSJJ02)
河南中医药大学研究生科研创新能力提升计划项目(2022KYCX057,2023KYCX043)。
关键词
黄芪甲苷
肺癌
机制研究
astragaloside IV
lung cancer
mechanism of action
